Germany located BioNTech will initially produce the vaccines at Sanofi facilities in Frankfurt, starting in the summer, according to a Sanofi statement Wednesday. The company did not reveal financial details of the agreement.

The French government has been pressing Sanofi to use its facilities to help make rival vaccines, given high demand and problems with supplies of the few vaccines that are already available.

According to Thomas Cueni, director of the International Federation of Vaccine Manufacturers, 76% of the world’s major vaccine manufacturing capacity is in Europe.

The French government has pressed Sanofi to use its facilities to help make vaccines from its rivals, given the high demand and supply problems.

“We are very conscious that the earlier vaccine doses are available, the more lives can potentially be saved,” Sanofi CEO Paul Hudson said in a statement.